Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
- Address
- Ul. Garncarska 11, 31-115 Krakow, Poland
Triple Negative Breast Cancer (TNBC)
The Department of Clinical Oncology at the Narodowy Instytut Onkologii is conducting studies that assess new immunotherapy approaches for triple‑negative breast cancer. Trials focus on measuring complete tumor disappearance after surgery and tracking survival without disease recurrence.
- Pathologic complete response evaluation
- Event‑free survival analysis
- Neoadjuvant and adjuvant immunotherapy
- Combination of checkpoint inhibitor with chemotherapy
Patients benefit from cutting‑edge treatment options while researchers gather data to improve long‑term outcomes.
Renal Cell Carcinoma
Investigators are testing the effectiveness of a checkpoint inhibitor as a single‑agent adjuvant therapy after surgical removal of the kidney. The study aims to determine whether this approach can extend overall survival for patients with renal cell carcinoma.
- Adjuvant therapy after nephrectomy
- Overall survival measurement
- Safety and tolerability assessment
- Long‑term disease‑free monitoring
The research supports the institute’s commitment to advancing care for patients with advanced kidney cancers.
Advanced Tumor Research
Across multiple solid tumor types, the clinic evaluates novel immunotherapeutic agents to improve response rates and survival. Studies include patients with advanced tumors and assess disease‑free and overall outcomes.
- Evaluation of disease‑free survival
- Overall survival endpoints
- Biomarker-driven patient selection
- Safety profiling of emerging treatments
The site’s multidisciplinary team collaborates to bring innovative therapies from bench to bedside.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 27 therapeutic areas and 15 of 415 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 395 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 83 by active trials.
- 1Merck Sharp & Dohme LLC32active
lock +82 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC79trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
lock Showing 1 of 437 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA) | AstraZeneca AB | Phase I/II | Not Recruiting | Jul 2021 | — |
IMP list
lock Showing 1 of 415 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 97 | Unknown | 2015-07-16 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.